Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(24):1827-1829; doi:10.1093/jnci/94.24.1827
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Schultz, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schultz, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 24, 1827-1829, December 18, 2002
© 2002 Oxford University Press

NEWS

Designer Molecule May Lead to New Treatments for Ocular Cancers

James Schultz

The first 10% of the full text of this article appears below.

Cure rates for nonmetastasized ocular cancer are very high—but at a steep price. Despite advances in radiation, chemotherapy, and laser therapies, enucleation, or surgical removal of the eye, is associated with the highest rate of cure. For adults, enucleation is tragedy enough. For children born with a genetic predisposition to eye cancer, enucleation can prove an even crueler fate, stealing vision just several years after birth and before language is even acquired or mastered.

As an alternative to eye removal, and to reduce intraocular tumor size or destroy tumors outright, physicians are exploring innovative uses of ultrasound, heat, cryogenics, targeted radiation "seeds," even reengineered viruses. The . . . [Full Text of this Article]

Research Funding

Novel Molecule

Stopping Further Growth


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?